National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Ovarian Germ Cell Tumors Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 05/22/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information







Treatment Option Overview






Stage I Ovarian Germ Cell Tumors






Stage II Ovarian Germ Cell Tumors






Stage III Ovarian Germ Cell Tumors






Stage IV Ovarian Germ Cell Tumors






Recurrent Ovarian Germ Cell Tumors






Get More Information From NCI






Changes to This Summary (05/22/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Questions about cancer?

1-800-4-CANCER
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to the Nation Finds Continued Declines in Cancer Rates
Treatment Option Overview

All patients except those with stage I, grade I immature teratoma and stage IA dysgerminoma require postoperative chemotherapy. With platinum-based combination chemotherapy, the prognosis for patients with endodermal sinus tumors, immature teratomas, embryonal carcinomas, choriocarcinomas, and mixed tumors containing 1 or more of these elements has improved dramatically.[1] As new and more effective drugs are developed, many of these patients will be candidates for newer clinical trials.

References

  1. Gershenson DM, Morris M, Cangir A, et al.: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8 (4): 715-20, 1990.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov